TheraRadar
Data updated: May 26, 2026

ZOHYDRO ER (hydrocodone bitartrate)

Trial Activity: Stable 1 active trials
Pain Approved 2013-10-25

Development Insights

M.D. Anderson Cancer Center conducting 1 trials (33%)
3 indications explored (Focused)
intra-abdominal cancer (1 trials)
pain (1 trials)
chronic pain (1 trials)
1
Indication
--
Phase 3 Trials
12
Years on Market

Details

Status
Discontinued
First Approved
2013-10-25
Patent Cliff
2034

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
CAPSULE, EXTENDED RELEASE

Companies

Active Ingredient: HYDROCODONE BITARTRATE

ZOHYDRO ER Approval History

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
84 FDA actions from 2013 to 2021
Mar 2021 SUPPL
Label · Labeling
Oct 2019 SUPPL
Label · Labeling
Sep 2018 SUPPL
Label · Labeling

What ZOHYDRO ER Treats

1 FDA approvals

Originally approved for its first indication in 2013 .

  • Other (1)
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT06585163 QEV-817-101 5R44DA055336 Ph 1 not yet recruiting Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension
NCT01081912 results posted ZX002-0801 Ph 3 completed Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain
NCT01115569 results posted ZX002-0802 Ph 3 completed Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ZOHYDRO ER FDA Label Details

View full patent landscape →
16 OB patents · 2 families · 76 international docs across 25 countries

ZOHYDRO ER Patents & Exclusivity

Latest Patent: Sep 2034

Patents (16 active)

US9486451 Expires Sep 12, 2034
US9713611 Expires Sep 12, 2034
US10092559 Expires Sep 12, 2034
US9452163 Expires Sep 12, 2034
US9132096 Expires Sep 12, 2034
US9326982 Expires Jul 25, 2033
US9265760 Expires Jul 25, 2033
US9421200 Expires Jul 25, 2033
US9433619 Expires Jul 25, 2033
US9339499 Expires Jul 25, 2033
US9610286 Expires Jul 25, 2033
US9333201 Expires Jul 25, 2033
US10028946 Expires Jul 25, 2033
US10456393 Expires Jul 25, 2033
US10722511 Expires Jul 25, 2033
US10322120 Expires Jul 25, 2033
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for ZOHYDRO ER

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2034
  • 576 active patents

Trial Analysis

  • 3 total trials
  • Stage: Stable

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment